拟无枝酸菌糖肽类和聚酮类抗生素的遗传信息及生物合成途径的研究进展  

Progress on Genetic Information and Biosynthetic Pathways of Glycopeptide and Polyketide Antibiotics of Amycolatopsis

作　　者：牛莎莎 张萍 牛春 Niu Sha-sha;Zhang Ping;Niu Chun(Ningxia Tairui Phamaceutical Co.,LTD.,Yinchuan 750100)

机构地区：[1]宁夏泰瑞制药股份有限公司,银川750100

出　　处：《国外医药（抗生素分册）》2024年第2期74-83,共10页World Notes on Antibiotics

摘　　要：拟无枝菌属(Amycolatopsis)是万古霉素和利福霉素等次生代谢产物的菌株,该菌属天然抗生素的分子遗传学已经有了广泛研究。由于抗生素耐药率的上升,寻找新的药物来对抗感染治疗已成为当务之急。了解代谢产物遗传信息的新进展有助于合理地操纵生物合成途径,以便于研发新型抗生素。本文综述了近年来通过Amycolatopsis基因组序列发现的糖肽类和聚酮类抗生素及其生物合成途径方面的成果。The genus Amycolatopsis produces secondary metabolites like rifamycin and vancomycin,which are widely used in agriculture and medicine.This genus's natural antibiotics'molecular genetics have been thoroughly researched.Due to the rise in antibiotic resistance,finding new drugs to fight infections has become a priority.New advances in understanding the genetic information of metabolites can help rationally manipulate biosynthetic pathways for the development of new natural antibiotics.In this review,we review the recent achievements of glycopeptide and polyketide antibiotics discovered by the Amycolatopis genome sequence and their biosynthetic pathways.

关 键 词：拟无枝酸菌 糖肽类抗生素 聚酮类抗生素 万古霉素 利福霉素 生物合成途径 

分 类 号：R978.1[医药卫生—药品]